Cosentyx under watch: new study tracks Real-World safety for skin and joint diseases
NCT ID NCT07243782
First seen Dec 17, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This study monitors the safety and effectiveness of the drug Cosentyx in Korean patients with three conditions: hidradenitis suppurativa (painful skin boils), pediatric plaque psoriasis (scaly skin patches in children), and juvenile idiopathic arthritis (childhood arthritis). About 76 participants will be followed to record any side effects and measure how well the drug controls their disease. The goal is to confirm the drug works safely in real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGSeoul, Seoul, 06973, South Korea
Conditions
Explore the condition pages connected to this study.